Compare Amphastar Pharmaceuticals Inc (AMPH) vs VF Corp (VFC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs VF Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while VF Corp trades at $16.74 (market cap $6.58B). The key difference: VF Corp is far larger — about 8× Amphastar Pharmaceuticals Inc's market cap, and VF Corp pays a 2.15% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | VFC | |
|---|---|---|
Market Cap | $826.08M | $6.58B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $21.55 |
52-Week Low | $16.87 | $11.66 |
Enterprise Value | $1.22B | $10.73B |
Dividend Yield | — | 2.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
VFC trades at $16.77, up 1.45% on the day, amid a mixed technical and fundamental backdrop. The stock is bearish on moving averages but shows neutral oscillators, with key support at $16. Recent earnings have been volatile, with a Q1 2026 miss after previous beats, while revenue has declined from $11.8B in 2022 to $9.5B in 2025. The company maintains a solid gross margin of 54.78% but reported a net loss of $189.72M for 2025. Analyst sentiment is mixed with a consensus price target of $20.00.
The outlook for VFC hinges on a successful turnaround, with projected net income turning positive in 2026. Near-term risks include weak consumer confidence and brand-specific challenges at Vans. The current valuation, with a P/S of 0.69, may appeal to value investors if operational improvements continue, but execution risks and high debt levels warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
